Pharmacogenetic Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
This study will determine which, if any, allelic variants of mycophenolic acid (MPA) metabolizing enzymes, drug transporters and drug targets are associated with the observed variation in pharmacokinetic and pharmacodynamic outcomes observed with CellCept usage. Patients participating in study ML17225 will be eligible for this pharmacogenetic investigation, and will have one additional blood sample taken during the study. The anticipated time on study treatment in study ML17225 is 1‐2 years, and the target sample size is 500+ individuals. This study is currently recruiting patients.
Epistemonikos ID: 67bccb0125bff1dadbdd24133fcc5f07984bc5cc
First added on: May 04, 2024